z-logo
Premium
Reduced erythrocyte lifespan measured by chromium‐51 in patients with type 2 diabetes undergoing long‐term hemodialysis
Author(s) -
Bomholt Tobias,
Oturai Peter,
Rix Marianne,
Almdal Thomas,
Knop Filip K.,
Rosthøj Susanne,
FeldtRasmussen Bo,
Hornum Mads
Publication year - 2021
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/hdi.12908
Subject(s) - medicine , hemodialysis , interquartile range , diabetes mellitus , hemoglobin , diabetic nephropathy , type 2 diabetes , gastroenterology , population , dialysis , endocrinology , environmental health
A reduced erythrocyte lifespan potentially explains the low hemoglobin A1c values found in hemodialysis patients. However, data supporting this notion in patients with type 2 diabetes is unclear. We evaluated the erythrocyte lifespan in patients with type 2 diabetes undergoing long‐term hemodialysis and investigated potential predictors of erythrocyte lifespan. Methods Long‐term hemodialysis patients with type 2 diabetes and type 2 diabetes patients without nephropathy (estimated glomerular filtration rate > 60 mL/min/1.73 m 2 ) were included. The erythrocyte lifespan was measured using chromium‐51 ( 51 Cr)‐labeled erythrocytes. Blood radiotracer activity was measured six to nine times over a period of 3–5 weeks to determine the erythrocyte lifespan of each patient. Biochemical markers were obtained five times over 16 weeks and associated with the erythrocyte lifespan. Findings Type 2 diabetes patients undergoing hemodialysis (N = 13) had a significantly shorter median erythrocyte lifespan of 49.7 (interquartile range [IQR] = 44.1–58.6) days compared with 64.2 (IQR = 62.6–83.5) days in the control group (N = 10) ( P ˂ 0.001) with a difference between medians of 14.5 (95% confidence interval = 8.1–38.8) days. In the hemodialysis group, no association could be detected between the erythrocyte lifespan and markers of hemolysis, level of inflammation, or urea. Discussion A reduced erythrocyte lifespan was detected in type 2 diabetes patients undergoing long‐term hemodialysis. This may contribute to the reduced hemoglobin A1c values observed in the type 2 diabetic hemodialysis population. An association could not be detected between the erythrocyte lifespan and biochemical markers of hemolysis or inflammation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here